ScreenerHero

PTHS Pelthos Therapeutics Inc.

AMEX · US · Healthcare · Biotechnology · pelthos.com
20.99USD-2.28%Mkt Cap: 80.36M $P/E: —

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagio…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap80.36M USD
Enterprise Value131.15M USD
Revenue (TTM)43.30M USD
Gross Profit7.43M USD
Net Income (TTM)-43.32M USD
Revenue/Share13.21 USD
Last Price20.99 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees92
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.78
PEG—
EV/EBITDA—
EV/Revenue3.03
P/S1.90
P/B-53.17
EPS (TTM)-27.53
EPS (Forward)-5.68
52W Range
18.1915% of range37.50
52W High37.50 USD
52W Low18.19 USD
Profitability
Gross Margin44.24%
Oper. Margin-101.41%
EBITDA Margin0.00%
Profit Margin-257.93%
ROE-111.41%
ROA-33.22%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.59M USD
CapEx (TTM)8.00M USD
FCF Margin-84.46%
FCF Yield-45.51%
Net Debt48.92M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.90
Current Ratio1.98
Quick Ratio1.21
Book Value/Sh-0.40 USD
Cash/Share6.32 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 2, 2025
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)53.14 USD
Upside (mean)+153.2%
Target Range45.00 USD – 64.00 USD
45.00+153.2% to mean64.00
# Analysts7
Ownership
Shares Out.3.83M
Float1.37M
Insiders50.10%
Institutions42.26%
Short Interest
Short Ratio2.0d
Short % Float4.54%
Short % Out.2.45%
Shares Short93.74K
Short (prev mo.)96.53K
Technical
SMA 5024.80 (-15.4%)
SMA 20024.95 (-15.9%)
Beta3.11
S&P 52W Chg15.77%
Avg Vol (30d)36.37K
Avg Vol (10d)27.41K
Technical Indicators
RSI (14)40.6
MACD-1.1451
MACD Signal-1.2196
MACD Hist.+0.0746
BB Upper24.40 USD
BB Middle21.78 USD
BB Lower19.15 USD
BB Width24.11%
ATR (14)1.482 USD
Vol Ratio (20d)0.51x